5 Best Small Cap Stocks To Buy For 2014

Cancer has been one of the hotter segments of the sizzling biotech sector this year with small cap cancer stocks�Genetics Inc (NASDAQ: CGIX), GTx, Inc (NASDAQ: GTXI) and MetaStat Inc (OTCMKTS: MTST) being among those involved in cancer research or treatment producing noteworthy news for investors to digest. Just consider the following:

Remember the HealthShares Emerging Cancer ETF (HHJ)? Bloomberg has a great article entitled ��essons Learned in the Exchange-Traded Fund Graveyard��which began by noting that there�are now 337 exchange-traded funds that have effectively died with more than 40 percent of those deaths taking place in the last 18 months. The article mentioned that Vanguard's John Bogle loved to hate the HealthShares Emerging Cancer ETF�(HHJ) when he wrote in a 2007 Wall Street Journal op-ed:���ith each passing day, the market segments available through ETFs seem to get narrower. (Can you believe that we now have a ��ealthShares Emerging Cancer��ETF?).��His point was that such funds contradict the principal concepts underlying original index fund of offering the broadest possible diversification. In other words and if you want to invest in a narrow biotech market segment like cancer, you will need to stick with individual cancer stocks. Cancer Genetics Gets an Upgrade. Yesterday, Feltl said it had learned that Roche and Cancer Genetics, which offers products and services that enable cancer diagnostics along with�treatments tailored to the specific genetic profile of�an individual,�have expanded their relationship to bring CGIX hospital program to Latin America and the Caribbean. They rate Cancer Genetics��shares�a Strong Buy and�raised their target price�to $30 from $17.50. On Wednesday, small cap Cancer Genetics rose 1.73% to $19.94 (CGIX has a 52 week trading range of $7.00 to $23.25 a share) for a market cap of $115.98 million plus shares are up 119.1% since last August. Cancer Genetics is also rising close to 3% in premarket trading right now.

Best Blue Chip Stocks To Watch Right Now: Sky-mobi Limited(MOBI)

Sky-mobi Limited engages in the operation of a mobile application store in the People?s Republic of China. It works with handset companies to pre-install its Maopao mobile application store on handsets and with content developers to provide users with applications and content titles. The users of its Maopao store could browse, download, and purchase a range of applications and content, such as single-player games, mobile music, and books. The company?s Maopao store enables mobile applications and content to be downloaded and run on various mobile handsets with hardware and operating system configurations. It also operates a mobile social network community, the Maopao Community, where it offers localized mobile social games, as well as applications and content with social network functions to its registered members. The company owns proprietary mobile application technology in the cloud computing, the MRP format, and SDK development environment. As of March 31, 2011, it had entered into cooperation agreements with approximately 523 handset companies to pre-install Maopao. The company was formerly known as Profit Star Limited and changed its name to Sky-Mobi Limited in October 2010. Sky-mobi Limited was incorporated in 2007 and is headquartered in Hangzhou, China.

Advisors' Opinion:

• [By Roberto Pedone]

  Another stock that's starting to move within range of triggering a big breakout trade is Sky-mobi (MOBI), which, through its subsidiaries, engages in the operation of a mobile application platform embedded on mobile phones to provide mobile application store and services in the People�s Republic of China. This stock has been red hot so far in 2013, with shares up a whopping 88%.

  If you look at the chart for Sky-mobi, you'll notice that this stock recently formed a triple bottom chart pattern at $3.31, $3.28 and $3.40 a share. That bottoming pattern occurred over the last two months. Shares of MOBI have now started to uptrend and flirt with its 50-day moving average of $3.76 a share. That move is quickly pushing MOBI within range of triggering a big breakout trade.

  Traders should now look for long-biased trades in MOBI if it manages to break out above some near-term overhead resistance levels at $3.71 to $3.83 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 145,934 shares. If that breakout triggers soon, then MOBI will set up to re-test or possibly take out its 52-week high at $4.96 a share. Any high-volume move above that level will then give MOBI a chance to tag its next major overhead resistance levels at $5.55 to $6.13 a share.

  Traders can look to buy MOBI off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.40 to $3.28 a share. One can also buy MOBI off strength once it takes out that breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Monica Gerson]

  Sky-mobi (NASDAQ: MOBI) is projected to report its Q2 results.

  Perfect World Co (NASDAQ: PWRD) is estimated to post its Q2 earnings at $0.41 per share on revenue of $150.56 million.

5 Best Small Cap Stocks To Buy For 2014: InterDigital Inc.(IDCC)

Interdigital, Inc. engages in the design and development of digital wireless technology solutions. The company offers technology solutions for use in digital cellular and wireless products and networks, including 2G, 3G, 4G, and IEEE 802-related products and networks. It holds patents related to the fundamental technologies that enable wireless communications. The company licenses its patents to equipment producers that manufacture, use, and sell digital cellular and IEEE 802-related products; and licenses or sells mobile broadband modem solutions, including modem IP, know-how, and reference platforms to mobile device manufacturers, semiconductor companies, and other equipment producers that manufacture, use, and sell digital cellular products. InterDigital?s solutions are incorporated in various products comprising mobile devices, such as cellular phones, tablets, notebook computers, and wireless personal digital assistants; wireless infrastructure equipment, such as base stations; and components, dongles, and modules for wireless devices. The company was founded in 1972 and is headquartered in King of Prussia, Pennsylvania.

Advisors' Opinion:

• [By Eric Volkman]

  InterDigital (NASDAQ: IDCC  ) is about to raise its global profile following an international patent licensing deal. The company announced that it has entered an agreement with Spain-based Teltronic Unipersonal for the latter to license a set of its 4G technologies. The terms of the arrangement were not disclosed.

5 Best Small Cap Stocks To Buy For 2014: China Metro-Rural Holdings Limited(CNR)

China Metro-Rural Holdings Limited, through its subsidiaries, primarily engages in the development and operation of agricultural logistics and trade centers in northeast China. It also involves in purchasing, processing, assembling, merchandising, and distributing pearls and jewelry products. The company markets its pearls and jewelry products to wholesale distributors and mass merchandisers in Europe, the United States, Hong Kong, and other parts of Asia. In addition, it develops, sells, and leases residential and commercial properties in Hong Kong and the People?s Republic of China. The company is based in Tsimshatsui, Hong Kong.

Advisors' Opinion:

• [By Katie Brennan]

  Canadian National Railway Co. (CNR) added 0.9 percent to C$104.93 and Canadian Pacific Railway Ltd. rose 1.7 percent to C$131.73.

  Niko Resources surged 3.4 percent to $8.64 after the company entered an agreement for a $60 million loan that will be funded by a group of institutional investors. Net proceeds from the loan will be used to fund working capital requirements.

5 Best Small Cap Stocks To Buy For 2014: Achillion Pharmaceuticals Inc.(ACHN)

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV; ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection; and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections; elvucitabine for HIV infection; and AC H-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Advisors' Opinion:

• [By Jon C. Ogg]

  Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) is getting destroyed on poor hep-C test results, and shares are down about 50%. Bank of America�Merrill Lynch downgraded it to Underperform from Buy after the news.

• [By Grace L. Williams]

  We took a look at Achillion Pharmaceuticals (ACHN) after two directors bought 40,000 shares for $394,800. Dennis Liotta bought 20,000 shares for $158,100 and Jason Fisherman bought 20,000 shares for $155,000. InsiderScore gave Liotta a nod, writing, ��iotta has been a smart buyer at Achillion in the past. He bought the same number of shares here, this time at a price 28% higher, which is the highest price he has paid for shares.��/p>

• [By Lisa Levin]

  Achillion Pharmaceuticals (NASDAQ: ACHN) rose 14.34% to $9.65 after the company reported that it has achieved 100% sustained virologic response rate from an eight week Phase 2 trial evaluating a ribavirin-free regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV.

• [By John Udovich]

  While Intercept Pharmaceuticals Inc (NASDAQ: ICPT) surged earlier this year and Achillion Pharmaceuticals, Inc (NASDAQ: ACHN) has surged this week after Merck & Co. Inc (NYSE: MRK) agreed to purchase hepatitis stock�Idenix Pharmaceuticals Inc (NASDAQ: IDIX) at a 239% premium, it seems the herd has realized that small cap Conatus Pharmaceuticals Inc (NASDAQ: CNAT) is also a liver disease stock as shares suddenly surged 56.69% on no apparent company news. But just what is�Conatus Pharmaceuticals and is it worth taking a chance on?